CN109153674B - 作为疟原虫天冬氨酸蛋白酶v抑制剂的亚氨基噻二嗪烷二氧化物衍生物 - Google Patents

作为疟原虫天冬氨酸蛋白酶v抑制剂的亚氨基噻二嗪烷二氧化物衍生物 Download PDF

Info

Publication number
CN109153674B
CN109153674B CN201780012863.2A CN201780012863A CN109153674B CN 109153674 B CN109153674 B CN 109153674B CN 201780012863 A CN201780012863 A CN 201780012863A CN 109153674 B CN109153674 B CN 109153674B
Authority
CN
China
Prior art keywords
formula
compound
methyl
ring
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780012863.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109153674A (zh
Inventor
T·德哈罗加西亚
M·A·洛
M·麦科斯
R·D·泰勒
朱昭宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN109153674A publication Critical patent/CN109153674A/zh
Application granted granted Critical
Publication of CN109153674B publication Critical patent/CN109153674B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780012863.2A 2016-02-23 2017-02-22 作为疟原虫天冬氨酸蛋白酶v抑制剂的亚氨基噻二嗪烷二氧化物衍生物 Expired - Fee Related CN109153674B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1603104.9 2016-02-23
GBGB1603104.9A GB201603104D0 (en) 2016-02-23 2016-02-23 Therapeutic agents
PCT/EP2017/054023 WO2017144517A1 (en) 2016-02-23 2017-02-22 Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors

Publications (2)

Publication Number Publication Date
CN109153674A CN109153674A (zh) 2019-01-04
CN109153674B true CN109153674B (zh) 2022-03-22

Family

ID=55753038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780012863.2A Expired - Fee Related CN109153674B (zh) 2016-02-23 2017-02-22 作为疟原虫天冬氨酸蛋白酶v抑制剂的亚氨基噻二嗪烷二氧化物衍生物

Country Status (10)

Country Link
US (1) US10464932B2 (https=)
EP (1) EP3419975B1 (https=)
JP (1) JP6831400B2 (https=)
CN (1) CN109153674B (https=)
BR (1) BR112018016196A2 (https=)
CA (1) CA3015271C (https=)
EA (1) EA034537B1 (https=)
ES (1) ES2886449T3 (https=)
GB (1) GB201603104D0 (https=)
WO (1) WO2017144517A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201805816D0 (en) * 2018-04-06 2018-05-23 Ucb Biopharma Sprl Therapeutic agents
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
CN110156608B (zh) * 2019-04-24 2022-04-01 深圳市第二人民医院 绿卡色林中间体对氯苯乙胺的合成方法
GB201906804D0 (en) 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021026884A1 (en) * 2019-08-15 2021-02-18 Merck Sharp & Dohme Corp. Antimalarial agents
CN114206856A (zh) * 2019-08-19 2022-03-18 Ucb生物制药有限责任公司 抗疟疾的六氢嘧啶类似物
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents
GB202010606D0 (en) 2020-07-10 2020-08-26 Ucb Biopharma Sprl Therapeutic agents
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents
WO2023152042A1 (en) 2022-02-08 2023-08-17 UCB Biopharma SRL Antimalarial hexahydropyrimidine analogues

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639135A (zh) * 2009-10-08 2012-08-15 先灵公司 作为bace抑制剂的亚氨基噻二嗪二氧化物化合物、组合物和它们的用途
CN102812006A (zh) * 2010-01-18 2012-12-05 Mmv疟疾药物投资公司 新型抗疟疾试剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527201A (ja) * 2003-06-06 2006-11-30 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
PT1699455E (pt) 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2014093190A1 (en) 2012-12-14 2014-06-19 Merck Sharp & Dohme Corp. Bace inhibitors of iminothiadiazine dioxides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639135A (zh) * 2009-10-08 2012-08-15 先灵公司 作为bace抑制剂的亚氨基噻二嗪二氧化物化合物、组合物和它们的用途
CN102812006A (zh) * 2010-01-18 2012-12-05 Mmv疟疾药物投资公司 新型抗疟疾试剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Transition State Mimetics of the Plasmodium Export Element Are Potent Inhibitors of Plasmepsin V from P. falciparum and P. vivax;Brad E. Sleebs et al.;《Journal of Medicinal Chemistry》;20140828;第57卷;第7644-7662页 *

Also Published As

Publication number Publication date
ES2886449T3 (es) 2021-12-20
US10464932B2 (en) 2019-11-05
EA034537B1 (ru) 2020-02-18
CA3015271A1 (en) 2017-08-31
GB201603104D0 (en) 2016-04-06
JP6831400B2 (ja) 2021-02-17
JP2019509337A (ja) 2019-04-04
CN109153674A (zh) 2019-01-04
EP3419975A1 (en) 2019-01-02
CA3015271C (en) 2023-08-01
US20190040053A1 (en) 2019-02-07
WO2017144517A1 (en) 2017-08-31
EA201891870A1 (ru) 2019-03-29
EP3419975B1 (en) 2021-06-23
BR112018016196A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
CN109153674B (zh) 作为疟原虫天冬氨酸蛋白酶v抑制剂的亚氨基噻二嗪烷二氧化物衍生物
US11136310B2 (en) Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors
US11001563B2 (en) SSAO inhibitor
DK2614061T3 (en) Quinoline and quinoxaline derivatives as kinase inhibitors
CA2693159C (en) Sulfonamides as trpm8 modulators
JP5243953B2 (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
TW202237600A (zh) 雙環衍生物
HK1054034B (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
WO2014067985A1 (en) Compounds for use in the treatment of parasitic diseases
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
CN104860890A (zh) T790m突变型egfr的抑制剂及其在制备抗肿瘤药物中的应用
JP2002255964A (ja) イミダゾピリジン誘導体
JP2005097276A (ja) 縮合ピリミジン誘導体およびその用途
BR112018010473B1 (pt) Composto, composição farmacêutica e uso do composto
JP2000191641A (ja) アミノグアニジンヒドラゾン誘導体、その製法及び剤
NZ626176B2 (en) Pyridinone and pyrimidinone derivatives as factor xia inhibitors
NZ626176A (en) Pyridinone and pyrimidinone derivatives as factor xia inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220322